GlucoTrack (NASDAQ:GCTK) Releases Earnings Results

GlucoTrack (NASDAQ:GCTK) released its earnings results on Thursday. The company reported $4.64 earnings per share for the quarter, FiscalAI reports.

GlucoTrack Trading Down 8.6%

GCTK traded down $0.49 on Friday, hitting $5.18. 14,005 shares of the company were exchanged, compared to its average volume of 699,180. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.27 and a current ratio of 3.27. The firm has a fifty day simple moving average of $6.57 and a two-hundred day simple moving average of $6.84. The stock has a market capitalization of $4.72 million, a PE ratio of 0.00 and a beta of 0.24. GlucoTrack has a 12 month low of $4.22 and a 12 month high of $468.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GlucoTrack stock. Bank of America Corp DE increased its position in GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,089 shares of the company’s stock after buying an additional 4,085 shares during the quarter. Bank of America Corp DE owned 0.85% of GlucoTrack worth $25,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 10.92% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.